Ambrx partners with Zhejiang Medicine - MarketLine Financial Deals

Ambrx partners with Zhejiang Medicine

Ambrx partners with Zhejiang Medicine - MarketLine Financial Deals
Ambrx partners with Zhejiang Medicine
Published Jun 16, 2013
2 pages — Published Jun 16, 2013
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Ambrx, Inc., a US-based biopharmaceutical company, has signed an agreement with Zhejiang Medicine Co., Ltd. (ZMC) to develop and commercialize ARX788, Ambrx's internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

  
Source:
Document ID
MA139808_130618
Country
Country
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Ambrx partners with Zhejiang Medicine" Jun 16, 2013. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Ambrx-partners-with-Zhejiang-Medicine-2052-95344>
  
APA:
MarketLine Financial Deals. (2013). Ambrx partners with Zhejiang Medicine Jun 16, 2013. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Ambrx-partners-with-Zhejiang-Medicine-2052-95344>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.